Biopsy-proven NAFLD in patients with obesity was related to increased circulating levels of ANGPTL8 (normal liver 11.94 ± 1.60 vs. NAFLD 20.00 ± 1.96 ng/mL, p = 0.003) in both stages of NAFLD and NASH (Figure 1b). Here, ANGPTL8 is linked to metabolic dysfunction-associated steatohepatitis.